Biotech Co.* (Symbol)

Pharma Co. (Symbol/Country)

Product

Disclosed Funding ($M)

Terms/Details (Date)

AltaRex Corp. (Canada;TSE:AXO)

Genesis Pharma SA (member of MSJ Group [Greece])

Altarex's OvaRex and other antibody-based immunotherapeutic cancer products

ND

Genesis gains rights to market the products in Greece, Turkey, Cyprus and the Balkans; AltaRex will supply the antibody for clinical study; Genesis will provide infrastructure for distribution and billing purposes and cover all remaining costs associated with regulatory approval in the region; resulting profits will be distributed equally to all parties (6/00)

AltaRex Corp. (Canada; TSE:AXO)

Medison Pharma (Israel)

AltaRex's OvaRex and other antibody-based cancer therapeutics

ND

Companies created a joint venture for commercialization in Israel and the Middle East; AltaRex will supply the antibody for clinical study in Irael both before and after U.S. approval; Medison will provide infrastructure for distribution and billing purposes; and will be responsible for local drug development costs; resulting profits from commercialization will be distributed equally (7/00)

Athersys Inc.*

Covance

Undisclosed therapeutic protein Biotechnology Services Inc. (subsidiary of Covance Inc. [NYSE:CVD])

ND

Covance will manufacture bulk product for preclinical and clinical studies (6/00)

Axiom Biotechnologies*

Biacore International (Sweden; BCOR)

Biacore will distribute Axiom's new high-through-put pharmacology system, HT-PS 100, on a worldwide

$4

Biacore made an equity investment of $4M in Axiom; Biacore has been granted an option to increase its stake in the company at a predetermined price; the agreement includes co-promotion rights to selected cell lines developed by Axiom and an option for Biacore to license Axiom's multi-channel, high-throughput system HT-PS Ultra (5/00)

Cell Pathways Inc. (CLPA)

Aventis Pharmaceuticals Inc. (unit of Aventis SA, France; NYSE:AVE)

Aventis' Nilandron for treatment of advanced prostate prostate cancer

ND

Cell Pathways gained rights to market Nilandron to urologists in the U.S. and Puerto Rico; Cell Pathways will receive a percentage of sales (7/00)

Cell Pathways Inc (CLPA)

Paladin Labs (Canada; TSE:PLB)

Aptosyn (exisulind) for treatment of pre-cancerous colon polyps in patients with familial adenomatous polyposis

ND

Paladin gains exclusive rights in Canada (7/00)

Cellomics Inc.*

Beckman Coulter Inc. (NYSE:BEC)

Cellomics' High Content Screening Technologies for drug discovery

ND

Companies will co-market Cellomics' ArrayScan II instrument and application software, HitKit Reagents and certain informatics products in North America and selected European countries; Beckman Coulter will exclusively distribute ArrayScan II and ArrayScan Kinetics Reader instruments, Cellomics Store and Cellomics Screen informatics products and will serve as sales agent for HitKit; companies will also create Cell Technology Centers of Excellence within academic and non-profit institutions and collaborate in mutual fields of interest (6/00)

Cel-Sci Corp. (AMEX:CVM)

Bio Science Contract Production Corp.

Multikine, a natural mixture of human cytokines now in Phase II trials for head and neck cancer

ND

Companies signed a long-term agreement under which Cel-Sci's trained staff will make the product at BSC's Baltimore facility (6/00)

Cephalon Inc. (CEPH)

Medtronic Inc. (NYSE:MDT)

Medtronic's Intrathecal Baclofen (ITB) Therapy for treatment of severe spasticity

ND

Cephalon is responsible for promoting ITB to neurologists under co-promotion agreement; Medtronic will provide training and support related to the device for ITB Therapy; agreement is for an initial one-year term, and will renew automatically unless terminated by either party (4/00)

Chiron Corp. (CHIR)

Aventis Pasteur (unit of Aventis SA [France; NYSE: AVE])

Menjugate (menigococcal C vaccine) and Fluad (adjuvenated influenza vaccine)

ND

Aventis will co-promote Menjugate in the UK and Ireland and distribute the product under its own label in the rest of Europe; Aventis will co-promote Fluad in Europe (7/00)

CollaGenex Pharmaceuticals Inc. (CGPI)

Willvonsder & Marchesani Ges.m.b.H.& Co. KG (Austria) and Karr Dental Ltd. (Switzerland)

CollGenex's Periostat for periodontal diseasefor periodontal disease

ND

W&M and Karr obtained rights to market Periostat in Austria and Switzerland; both will pay fees associated with the regulatory approvals of Periostat and purchase the drug from CollaGenex via its UK subsidiary, CollaGenex International Ltd. (6/00)

ICN Pharmaceuticals Inc. (NYSE:ICN)

Eli Lilly and Co. (NYSE:LLY)

Cesamet (nabilone) for management of severe nausea and vomiting associated with cancer chemotherapy

ND

ICN will market and distribute Cesamet in Canada (6/00)

Kos Pharmaceuticals (KOSP)

DuPont Pharmaceuticals Co. Inc. (unit of DuPont [NYSE:DD])

Development collaboration focuses on the commercialization of Nicostatin, a single-tablet formulation that integrates all the benefits of Niaspan (proprietary formulation of niacin) with a statin

$80

KOS received $20M from DuPont through an initial equity investment; Kos will receive from DuPont additional equity investments of up to $10M and a $17.5M milestone payment at the time Nicostatin is approved by the FDA; DuPont will also provide $32.5M for future development (6/00)

Nabi (NABI)

Collaborative BioAlliance Inc. (affiliate of The Collaborative Group Ltd.)

StaphVAX (Staphylococcus aureus type 5 and type 8 capsular polysaccharide conjugate vaccine)

ND

Collaborative BioAlliance will manufacture the vaccine at its cGMP manufacturing facility in Smithfield, R.I. (5/00)

Vivus Inc. (VVUS)

Abbott Laboratories (NYSE:ABT)

Vivus' transurethral products Muse (alprostadil) and Alibra for the treatment of erectile dysfunction

ND

Abbott gains exclusive rights for Muse and Alibra in selected markets, including Europe, Japan, Australia, New Zealand and South and Central America; Abbott has the option to co-develop and license future Vivus transurethral products in this territory (6/00)

SkyePharma plc (UK; SKYE)

Paladin Labs Inc.

SkyePharma's DepoCyt (injectable sustained-release cytarabine)

$1

Paladin Labs gains exclusive Canadian marketing and distribution rights for DepoCyt; SkyePharma will receive an up-front payment of $1M, additional milestone payments tied to future events and a significant share of future revenues (7/00)

NOTES

# The information in the chart does not cover agreements between biotech companies or agricultural agreements.

* Private companies are indicated with an asterisk; unless otherwise noted, stock symbols listed are on the NASDAQ market.

ND = Not disclosed, reported and/or available

AMEX = American Stock Exchange; LSE = London Stock Exchange; NYSE = New York Stock Exchange; OTC BB = Over The Counter Bulletin Board.

No Comments